Description

Ociperlimab is a high-purity, investigational monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains). This compound is of significant interest for its potential role in immuno-oncology, specifically designed to block the TIGIT checkpoint pathway and enhance anti-tumor immune responses. It is primarily utilized by pharmaceutical R&D departments, biotechnology firms, and clinical research organizations engaged in the development of novel cancer immunotherapies. Ociperlimab CAS NO 2342597-93-5 represents a critical reagent for preclinical studies and therapeutic candidate development.

Application

• Immuno-Oncology Research: A key reagent for studying the TIGIT immune checkpoint pathway and its role in tumor microenvironment suppression.
• Therapeutic Antibody Development: Serves as a reference standard or active pharmaceutical ingredient (API) in the formulation of novel biologic cancer therapies.
• Preclinical & In-Vitro Studies: Used in cell-based assays, mechanism-of-action studies, and efficacy testing to evaluate combination therapies with other checkpoint inhibitors.
• Biomarker Discovery: Employed in research to identify patient populations that may respond best to TIGIT-targeted treatments.
• Process Development & Scale-Up: Supports downstream process development, purification, and analytical method validation for biomanufacturing.
• Clinical Trial Material: Supplied under GMP conditions for use in investigational new drug (IND) applications and subsequent clinical trials.

Basic Information

Product Name	Ociperlimab
CAS No.	2342597-93-5
Molecular Formula	Contact for details
Molecular Weight	Approx. 145-150 kDa (Contact for exact specification)
Synonyms	Anti-TIGIT Monoclonal Antibody; BGB-A1217; TIGIT Inhibitor BGB-A1217; BGB A1217; Ociperlimab (BGB-A1217); Recombinant Anti-TIGIT Antibody; Immunoglobulin G1, anti-(human TIGIT) (human monoclonal BGB-A1217 γ1-chain), disulfide with human monoclonal BGB-A1217 κ-chain, dimer
EINECS	Contact for details

Quality Control

Our Ociperlimab is manufactured and controlled under a stringent quality management system. Each batch is subjected to a comprehensive panel of analytical tests to ensure identity, purity, potency, and consistency. Specifications are aligned with ICH guidelines and relevant pharmacopeial standards for biologic APIs. A detailed Certificate of Analysis (COA), including data for purity (by SEC-HPLC and CE-SDS), bioactivity (binding ELISA or cell-based assay), endotoxin levels, and sterility (where applicable), is provided with every shipment. Research and GMP grades are available to suit different development phases.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized powder at -20°C or below. Reconstituted or liquid formulations should typically be stored at 2-8°C for short-term use or aliquoted and stored at ≤ -20°C to avoid repeated freeze-thaw cycles. This product is hygroscopic (moisture-sensitive); ensure containers are sealed under controlled, dry conditions.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear solution
Identification (SEC-HPLC / MS)	Conforms to reference standard
Purity (SEC-HPLC)	≥ 95.0% (Monomer)
Purity (CE-SDS, reduced)	≥ 90.0% (Main peak)
Protein Content (A280)	90% - 110% of label claim
Potency (Binding ELISA)	EC50 within defined range
Endotoxin	< 1.0 EU/mg
pH	6.0 - 7.5 (for solution)

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.